Genmab A+s

Hoffmann-La Roche Inc.

Roche Palo Alto LLC

F. Hoffmann-La Roche Ag

Jan Van De Winkel

Paul Parren

Aran Frank Labrijn

Yvo Graus

Janine Schuurman

Tom Vink

Martine Van Vugt

Frank Rebers

Bart De Goeij

Edward Norbert Van Den Brink

Erhard Kopetzki

Rene Hoet

Ole Baadsgaard

Patrick Van Berkel

David Satijn

Kay-Gunnar Stubenrauch

Ralf Schumacher

Beat Steiner

Anne Stern

Joyce Meesters

Joost J Neijssen

Jacques Himber

Willem Karel Bleeker

Michel De Weers

Miranda Jansen-Molenaar

Dorothee Kling

Simone De Haij

Thilo Riedl

Stefan Seeber

Sandra Verploegen

Maria Elena Fuentes

Pamela Strein

Olaf Mundigl

Klaus-Peter Kuenkele

Elsie M Eugui

Martin Lanzendoerfer

Frank Beurskens

Ewald T J Van Den Bremer

Steen Lisby

Tim Walseth

Rob Aalberse

Judith Oprins

Joseph Endl

Martine Vriesema-van Vugt

Rob N De Jong

David P E Satijn

Esther Cornelia Wilhelmina Breij

Marijn Van Der Neut Kolfschote

Vibeke Miller Breinholt

Eva Ehrnrooth

Mischa Houtkamp

Maroeska Oudshoorn

Frank Everhardus Martinus Rebers

Wim Bleeker

Pamela Braemer

Joerg Thomas Regula

Adelbert Grossmann

Arnout F Gerritsen

Ignace Lasters

Martin John Glennie

Klaus Edvardsen

Josef Endl

Jessica Teeling

Stefan Loverix

Jan Olaf Stracke

Sebastian Neumann

Marijn Van Der Neut Kolfschoten

Sigrid Ruuls

Rene M A Hoet

Jeroen Lammerts Van Bueren

Thomas Valerius

Michael Dechant

Wencke Weisner

Sven Berger

Sandra Vereecken-Verploegen

Novel heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins.

Heterodimeric antibody Fc-containing proteins and methods for production thereof

Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

Monoclonal antibodies against c-Met

Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.

Antibodies against human CD38

Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

Monoclonal antibodies against HER2

The invention relates to an ex vivo method for the generation of a bispecific antibody, comprising the steps of: a) providing a first antibody having a first binding specificity, wherein said first antibody comprises an IgG4-like CH3 region, b) providing a second antibody having a second binding specificity which differs from said first binding specificity, wherein said second antibody comprises an IgG4-like CH3 region, c) incubating said first and second antibodies together under reducing conditions which allow the cysteines in the core hinge region to undergo disulfide-bond isomerization, and d) obtaining a bispecific antibody. The invention furthermore relates to bispecific antibodies obtainable by the method of the invention.

Bispecific antibodies and methods for production thereof

Monoclonal antibodies against HER2 epitope

The present invention relates to novel stabilized IgG4 antibodies, to methods of producing such antibodies and to uses of such antibodies as a medicament. In a main aspect, the invention relates to a stabilized IgG4 antibody, comprising a heavy chain and a light chain, wherein said heavy chain comprises a human IgG4 constant region having a substitution of the Arg residue at position (409), the Phe residue at position (405) or the Lys residue at position (370).

Stable IgG4 antibodies

The invention relates to novel non-human transgenic animals, which upon antigenic stimulation are capable of producing monovalent antibodies binding to a selected antigen, modified heavy chain transgenes, methods for producing the non-human transgenic animals, methods for immunizing the non-human transgenic animals for as well as monovalent antibodies obtainable by such immunization methods.

Recombinant IgG4 monovalent antibodies

The present invention provides monovalent antibodies with a long half-life when administered in vivo, methods of making such monovalent antibodies, pharmaceutical compositions comprising such antibodies, and uses of the monovalent antibodies.

Recombinant monovalent antibodies and methods for production thereof

The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of IgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed.

Antibody variants having modifications in the constant region

Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related anti-body-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.

Human antibodies against tissue factor and methods of use thereof

Growing community of inventors

Zeist, Netherlands

Jan Van De Winkel